Renisamin
Kidney cytamin — Khavinson-school organ peptide fraction, oral tablet
Renisamin (Kidney cytamin — Khavinson-school organ peptide fraction, oral tablet) is a longevity & bioregulators research compound. A polypeptide fraction extracted from animal kidney, 155mg per tablet. The only renal result this school has published belongs to EDL, a synthetic tripeptide, given by injection to rodents with chemically or ischemically injured kidneys. A protective effect in acute injury is a different claim from support of a kidney that is working, and the direction of the two claims is not the same: the first is rescue, the second is maintenance, and no experiment in this school has tested the second.
Renisamin quick facts
| Route | Oral |
| Frequency | Not established · Not established |
| Half-life | Not characterized — no analytical method for this preparation has been published |
| Forms | Oral |
| Evidence level | No published study of this product. The renal result in this school is a synthetic tripeptide injected into rodents with acute kidney injury. |
A kidney product is the one place where an unassayed animal-protein tablet deserves the opposite of the benefit of the doubt. Nobody has published what is in it, nobody has published a renal dose adjustment for it, and there is no analytical method that would let a laboratory look for it in blood or urine. eGFR, cystatin C and urine albumin-to-creatinine ratio are the measurements that would settle whether it does anything, and a search for the product name on 8 September 2026 returned zero records of anyone taking them.
How Renisamin works
A polypeptide fraction extracted from animal kidney, 155mg per tablet. The only renal result this school has published belongs to EDL, a synthetic tripeptide, given by injection to rodents with chemically or ischemically injured kidneys. A protective effect in acute injury is a different claim from support of a kidney that is working, and the direction of the two claims is not the same: the first is rescue, the second is maintenance, and no experiment in this school has tested the second.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get Renisamin
Buy Renisamin at RUPharma →The evidence for Renisamin
Graded by what exists behind each claim.
✅ Clinically validated
- None. A PubTator3 search of PubMed for this product's name, run 8 September 2026, returned zero records — no trial, no case series, no pharmacokinetic study, no adverse event report. Nobody has looked, which is a different statement from nobody having found anything. Creatinine and eGFR are already on the metabolic panel most readers run twice a year, and cystatin C is the better measurement because it does not move with muscle mass.
📊 Correlative data
- The school's only renal result is the synthetic tripeptide EDL, given parenterally to rodents with acute kidney injury of different origins (Zamorskii 2017). Different molecule, different route, and a rescue experiment rather than a maintenance one.
- Calf-tissue polypeptides on organotypic cultures at 0.01-100 ng/ml (Ryzhak 2015) is the concentration language the whole class rests on.
🧪 Theoretical / extrapolated
- Protection against an acute insult and support of a working organ are not the same claim, and the school's own experiment predicts nothing measurable in a kidney that has not been injured.
- The kidney is where small peptides are cleared, so a product aimed at declining kidney function is a product whose own elimination route is the thing declining — and no renal dose adjustment has been published, because no dose has.
- eGFR, cystatin C and urine albumin-to-creatinine ratio would settle it. None has been reported.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Renisamin actually does
The school's one kidney result is a rescue experiment, and this product is sold as maintenance. Zamorskii 2017 reports a nephroprotective effect of the tripeptide EDL in rodent models of acute kidney injury of different origins. Read the design rather than the conclusion: an animal's kidney is deliberately damaged, a defined three-residue synthetic peptide is given, and the damage is smaller than in controls. That is a claim about limiting an insult. It is not a claim that anything improves in a kidney that is working normally, and the two directions are not interchangeable.
What is in the pack. A 155 mg tablet of a nucleoprotein fraction extracted from animal kidney, 40 to a pack, at $42. No published composition, no assay, no dissolution data, and no analytical method by which a laboratory could look for it in blood or urine. Ryzhak 2003 describes the manufacturing principle for the class and the screening applied to it, not the contents of a finished product.
The class premise and its kidney-specific version. The claim is that peptides released from an organ fraction regulate gene expression in the matching organ Khavinson 2021, with the supporting cell work showing tissue-matched effects on differentiation in aging tissue Khavinson 2012. For a kidney product that would have to mean measurable change in filtration, tubular handling or albumin leak. All three are routine measurements. None has been reported.
The irony that belongs on this page and no other. The kidney is where small peptides go to be cleared. Filtered peptides are reabsorbed and hydrolyzed in the proximal tubule, which is why peptide-drug exposure rises when filtration falls. A product marketed at people with declining kidney function is therefore a product whose own elimination route is the thing being declined — and nobody has published a renal dose adjustment for it, because nobody has published a dose.
Cell, rodent, human — and where it stops
The search and the zero. A PubTator3 query of PubMed for renisamin, run 8 September 2026, returned zero records. The whole page is therefore built out of experiments on other substances, and each sentence says which.
The animal rung: right organ, wrong molecule, wrong route, wrong direction. Zamorskii 2017 used EDL, a synthetic tripeptide, given parenterally, in acute injury. The product is an undefined extract, given by mouth, to people with no acute injury at all. Four differences in one comparison, and every marketing claim for this shelf is built by ignoring all four.
The cell rung. Ryzhak 2015 applied calf-tissue polypeptide preparations to organotypic cultures at 0.01 to 100 ng/ml. Nanograms per milliliter, pipetted onto tissue. That is the concentration language the whole class rests on, and it is worth carrying to every page in the line because it is the number vendors never print.
The human rung. Khavinson 2001 is a 2001 Russian paper on cytamines for professional ability and longevity in servicemen, by the school's own founder. It is the top of the ladder for this product family and it reports no renal endpoint. There is no trial of a kidney cytamin in anyone, healthy or otherwise.
Renisamin pharmacokinetics — how much of it actually gets in
What degrades it. Acid and pepsin, then pancreatic proteases, then brush-border peptidases, reducing a nucleoprotein complex to free amino acids and di- and tripeptides. Nothing about a kidney extract is chemically different from any other tissue extract in that sequence, and no protection from it is claimed for this product.
The oral barrier, then the elimination barrier — and the second one is what makes this page different. No oral bioavailability figure has ever been published for this preparation, so the fraction that gets past the gut wall is unknown. Whatever crosses it is cleared largely by the kidney, because that is how small peptides leave the body: filtered at the glomerulus, taken up and hydrolyzed in the proximal tubule. In a person with an estimated glomerular filtration rate of 30 ml/min rather than 90 ml/min, exposure to any renally cleared substance rises roughly threefold at the same dose. That arithmetic is standard for every renally cleared drug and it has never been done for this tablet.
The comparator, and the direction it points. Every demonstrated effect in this school's renal work came from an injection of a defined peptide Zamorskii 2017, which starts with the full dose in blood and bypasses the gut entirely. No injectable kidney extract exists in this catalog to compare against, so there is not even a ceiling figure to reason from. No half-life can be stated because no analytical method has been published.
The protein load nobody mentions. A 155 mg tablet is a trivial protein load in absolute terms — roughly a thousandth of a typical day's intake. It is named here because it is the one quantitative statement that can honestly be made about this product's burden on a kidney, and because the opposite claim, that it meaningfully loads the kidney, would be as unsupported as the claim that it protects one.
What would have to be true, and how you would know it was not
Four predictions, and the first two are on every standard renal panel already.
1. Creatinine and eGFR from a CMP, baseline and end of course. Already on the comprehensive metabolic panel most readers run twice a year, so the marginal cost is zero. Prediction: no change outside the assay's own variability, which for creatinine is larger than most people realize and is the reason a single reading never means much.
2. Cystatin C, because it is the better measurement and almost nobody orders it. It is independent of muscle mass, which matters enormously in this readership, where a high-protein diet and heavy training push creatinine up without anything being wrong with the kidney. If a reader is going to test one thing on this page, this is the one, and it has never been reported for this product.
3. Urinalysis with albumin-to-creatinine ratio. Albumin leak is the earliest signal of glomerular damage and the one endpoint a kidney product should plausibly touch. It is a urine sample. Zero published records of this tablet report it.
4. Against the product: the model that supports it predicts nothing here. Zamorskii 2017 demonstrated protection against an acute insult. In a person with no insult, the mechanism as described has nothing to protect against, so the honest prediction from the school's own experiment is no measurable change in a healthy kidney. A product whose supporting evidence predicts no effect in its buyer is worth naming as exactly that.
What nobody has tested yet
Nobody has published a renal dosing statement. Every renally cleared medicine carries one, because exposure rises as filtration falls. This product is aimed at exactly the population where that adjustment matters and has no dose to adjust, no analyte to measure and no study to base it on.
Nobody has looked for it in urine. If any peptide from this tablet is absorbed and renally cleared, urine is where it would concentrate, and a urine sample is the least invasive specimen in medicine. One volunteer, one pack, and mass spectrometry on timed urine collections would answer the absorption question outright.
Nobody has tested the extract in the model the tripeptide passed. Zamorskii 2017 is a published, repeatable rodent protocol. Running it with this extract instead of EDL would either give the class its first organ-specific animal result for a sold product or show that extract and defined peptide are not interchangeable. Nobody has published either outcome.
Extrapolation, labeled as such. If the transport argument is right and the active species are two- and three-residue fragments Khavinson 2023, then the kidney tablet and every other tablet in the line deliver the same fragments and differ only in label. The experiment that settles it is a proteomic comparison of two packs, and its absence after thirty years of sales is itself informative.
Renisamin — its own safety story, not its class's
Three things specific to an oral extract of animal kidney.
No adverse events, because no studies. The 8 September 2026 search returned nothing. There has never been a trial, a registry or a case series in which a side effect could have been captured, so the empty column measures the literature and not the product.
The mineral content is unpublished, and for this organ that is the specific gap. Animal tissue carries potassium and phosphate. Anyone with reduced kidney function is routinely advised to watch both, and no vendor publishes either figure for this tablet. At 155 mg the amounts involved are almost certainly small; the point is that almost certainly is the strongest statement available, because the analysis has never been published. That is a different sentence from a reassurance, and it is the honest one.
The sourcing question the school partly answers. Ryzhak 2003 states that the industrial process for this class uses organs from young animals and that testing indicates the technology excludes infectious agents. That is the manufacturer's own school on the class, not an independent certificate for a pack. Species, country of origin and animal age are published by no vendor of this product, and a buyer cannot verify any of it.
Sources read for this page
- Zamorskii II, Shchudrova TS, Lin'kova NS, Nichik TE, Khavinson VKh. Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different Genesis. Bulletin of Experimental Biology and Medicine 2017;163(3):389–393 · PMID 28744634
- Ryzhak AP, Chalisova NI, Lin'kova NS, Khalimov RI, Ryzhak GA, Zhekalov AN. [Polypeptides influence on tissue cell cultures regeneration of various age rats]. Advances in Gerontology 2015;28(1):97-103 [Russian] · PMID 26390619
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 · PMID 34834147
- Ryzhak GA, Nekrasov PA, Kiselev OI, Khavinson VKh. Study of protein components of natural peptide regulators. Bulletin of Experimental Biology and Medicine 2003 · PMID 12717513
- Khavinson VKh, Cherniak SI, D'iakonov MM. [Cytamines--preparations for maintaining high professional ability and longevity in servicemen]. Voenno-Meditsinskii Zhurnal 2001 [Russian] · PMID 11338817
- Khavinson VK, Linkova NS, Rudskoy AI, Petukhov MG. Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters. Biomolecules 2023;13(3):552 · PMID 36979488
- Khavinson VKh. Peptides tissue-specifically stimulate cell differentiation during their aging. Bulletin of Experimental Biology and Medicine 2012 · PMID 22808515
Renisamin — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Renisamin — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Renisamin moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
- Dose range and how to work up to it
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Renisamin in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Renisamin
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Renisamin — frequently asked questions
What is Renisamin?
Renisamin (Kidney cytamin — Khavinson-school organ peptide fraction, oral tablet) is a longevity & bioregulators research compound. A polypeptide fraction extracted from animal kidney, 155mg per tablet. The only renal result this school has published belongs to EDL, a synthetic tripeptide, given by injection to rodents with chemically or ischemically injured kidneys. A protective effect in acute injury is a different claim from support of a kidney that is working, and the direction of the two claims is not the same: the first is rescue, the second is maintenance, and no experiment in this school has tested the second.
Where can I find Renisamin dosing and protocols?
Dosing, the reconstitution calculator and Coach Cam's full Renisamin protocol are available to members inside Skool. This public page covers what Renisamin is, how it works and the evidence.
What is the half-life of Renisamin?
Renisamin has an approximate half-life of Not characterized — no analytical method for this preparation has been published, which is part of what determines how often it's dosed.
What's the evidence behind Renisamin?
Current evidence level: No published study of this product. The renal result in this school is a synthetic tripeptide injected into rodents with acute kidney injury.. Renisamin is offered for research purposes only and is not an approved medicine.
What Renisamin is used for
Renisamin appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.